BRPI1015097A2 - uso de um composto, composto, composição farmacêutica, método para tratamento de uma condição ou distúrbio no qual os canais de cálcio do tipo t ou canais de sódio regulados por voltagem estão envolvidos, composto ou um sal farmaceuticamente aceitável do mesmo e uso de um composto ou um sal farmaceuticamente aceitável do mesmo. - Google Patents

uso de um composto, composto, composição farmacêutica, método para tratamento de uma condição ou distúrbio no qual os canais de cálcio do tipo t ou canais de sódio regulados por voltagem estão envolvidos, composto ou um sal farmaceuticamente aceitável do mesmo e uso de um composto ou um sal farmaceuticamente aceitável do mesmo.

Info

Publication number
BRPI1015097A2
BRPI1015097A2 BRPI1015097A BRPI1015097A BRPI1015097A2 BR PI1015097 A2 BRPI1015097 A2 BR PI1015097A2 BR PI1015097 A BRPI1015097 A BR PI1015097A BR PI1015097 A BRPI1015097 A BR PI1015097A BR PI1015097 A2 BRPI1015097 A2 BR PI1015097A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
disorder
involved
Prior art date
Application number
BRPI1015097A
Other languages
English (en)
Inventor
Shimada Kaoru
Morita Mikio
Watanabe Shuzo
Inoue Tadashi
Yamagishi Tatsuya
Arano Yoshimasa
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of BRPI1015097A2 publication Critical patent/BRPI1015097A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1015097A 2009-05-29 2010-05-31 uso de um composto, composto, composição farmacêutica, método para tratamento de uma condição ou distúrbio no qual os canais de cálcio do tipo t ou canais de sódio regulados por voltagem estão envolvidos, composto ou um sal farmaceuticamente aceitável do mesmo e uso de um composto ou um sal farmaceuticamente aceitável do mesmo. BRPI1015097A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21332409P 2009-05-29 2009-05-29
US27258109P 2009-10-07 2009-10-07
US28253410P 2010-02-26 2010-02-26
PCT/JP2010/003649 WO2010137351A1 (en) 2009-05-29 2010-05-31 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

Publications (1)

Publication Number Publication Date
BRPI1015097A2 true BRPI1015097A2 (pt) 2019-09-24

Family

ID=43222477

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015097A BRPI1015097A2 (pt) 2009-05-29 2010-05-31 uso de um composto, composto, composição farmacêutica, método para tratamento de uma condição ou distúrbio no qual os canais de cálcio do tipo t ou canais de sódio regulados por voltagem estão envolvidos, composto ou um sal farmaceuticamente aceitável do mesmo e uso de um composto ou um sal farmaceuticamente aceitável do mesmo.

Country Status (10)

Country Link
US (2) US9101616B2 (pt)
EP (2) EP2435407B1 (pt)
JP (1) JP5685203B2 (pt)
KR (1) KR101605061B1 (pt)
CN (3) CN105254557A (pt)
BR (1) BRPI1015097A2 (pt)
CA (1) CA2761639C (pt)
HK (2) HK1217189A1 (pt)
MX (1) MX2011012712A (pt)
WO (1) WO2010137351A1 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
CN105254557A (zh) * 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2608474T3 (es) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Proceso de producción de compuestos indol cycloalkylcarboxamido
WO2012001040A1 (en) * 2010-07-02 2012-01-05 Syngenta Participations Ag Novel microbiocidal dioxime ether derivatives
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
CN103249721B (zh) * 2010-10-18 2016-10-12 拉夸里亚创药株式会社 作为ttx-s阻滞剂的芳胺衍生物
RU2456266C1 (ru) * 2011-04-06 2012-07-20 Максим Эдуардович Запольский Производные 4,4'-бифениламидов, обладающие фармакологической активностью, и лекарственные средства на их основе
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
JP2014527511A (ja) 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
UA111746C2 (uk) 2011-07-08 2016-06-10 Х. Луннбек А/С Позитивні алостеричні модулятори нікотинового рецептора ацетилхоліну
HRP20180913T1 (hr) 2011-07-08 2018-07-27 H. Lundbeck A/S Pozitivni alosterni modulatori receptora nikotinskog acetilkolina
JP2015508785A (ja) * 2012-03-02 2015-03-23 ジェネンテック， インコーポレイテッド ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体
US10266490B2 (en) * 2012-03-16 2019-04-23 Georgetown University Radioprotector compounds
IN2014MN01982A (pt) 2012-04-25 2015-07-10 Raqualia Pharma Inc
WO2014006120A1 (en) 2012-07-06 2014-01-09 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
CA2898653C (en) * 2013-01-31 2021-09-28 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
RS56015B1 (sr) 2013-01-31 2017-09-29 Vertex Pharma Piridon amidi kao modulatori natrijumovih kanala
EP2961403A4 (en) * 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
EP2968210B1 (en) * 2013-03-12 2024-09-11 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
US9566261B2 (en) 2013-03-12 2017-02-14 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
ES2687481T3 (es) 2013-03-15 2018-10-25 Chromocell Corporation Moduladores del canal de sodio para el tratamiento del dolor
CN104277033B (zh) * 2013-07-02 2017-03-08 湖南化工研究院 N‑(芳基烷基)芳氧苯氧羧酸酰胺类化合物及其制备方法与应用
AU2014318979B2 (en) 2013-09-10 2019-03-28 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US9745287B2 (en) 2013-12-20 2017-08-29 Purdue Pharma L.P. Pyrimidines and use thereof
JP6337124B2 (ja) 2013-12-23 2018-06-06 パーデュー、ファーマ、リミテッド、パートナーシップ インダゾール及びその使用
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
JP6526023B2 (ja) 2014-01-24 2019-06-05 パーデュー、ファーマ、リミテッド、パートナーシップ ピリジン類及びピリミジン類並びにその使用
US9452986B2 (en) * 2014-02-06 2016-09-27 Abbvie Inc. 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
AU2015217185B2 (en) 2014-02-12 2018-04-05 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
EP3110415A4 (en) 2014-02-28 2017-12-13 The Texas A & M University System Compositions and methods for inhibition of mycobacteria
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
EP3193610A4 (en) * 2014-09-09 2018-04-04 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes
US10246426B2 (en) * 2014-09-15 2019-04-02 Idorsia Pharmaceuticals Ltd Triazole compounds as T-type calcium channel blockers
CN108290881B (zh) 2015-09-28 2021-12-07 健泰科生物技术公司 治疗性化合物和其使用方法
EP3404021A4 (en) * 2016-01-12 2019-09-11 Nippon Chemiphar Co., Ltd. VOLTAGE-RELATED T-TYPE CALCIUM CHANNEL INHIBITOR
CN105963687A (zh) * 2016-04-27 2016-09-28 张金凤 一种用于治疗慢性盆腔疼痛的复方制剂及其制备方法
US11370761B2 (en) 2017-01-23 2022-06-28 Nippon Chemiphar Co., Ltd. Voltage-dependent T-type calcium channel inhibitor
ES2963044T3 (es) 2017-03-13 2024-03-25 Raqualia Pharma Inc Derivados de tetrahidroquinolina como antagonistas del receptor P2X7
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
PT3487839T (pt) * 2017-06-20 2021-02-11 Raqualia Pharma Inc Derivados de amida como bloqueadores de nav1.7 e nav1.8
EP3676248A4 (en) 2017-08-31 2021-04-14 RaQualia Pharma Inc. BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
GB2571978A (en) * 2018-03-15 2019-09-18 Andre Fisahn Uses, compositions and methods
AU2019302534B2 (en) * 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
US20220363667A1 (en) 2018-07-17 2022-11-17 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
IL280904B2 (en) * 2018-09-07 2025-01-01 Sumitomo Chemical Co Method for producing a cyclopropane compound
CN110885328B (zh) * 2018-09-10 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
IL284011B2 (en) * 2018-12-17 2024-12-01 Pharma Mar Sa Anticancer compounds
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
IL296035A (en) 2020-03-06 2022-10-01 Vertex Pharma Methods of treating apol-1 dependent focal segmental glomerulosclerosis
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
JP7466664B2 (ja) * 2020-07-31 2024-04-12 深▲川▼市橄欖生物医薬科技有限公司 ピラジン化合物およびその調製方法と使用
MX2023001384A (es) * 2020-08-06 2023-04-26 Chdi Foundation Inc Compuestos de heterobiarilo y agentes de imagenologia para imagenologia de proteina huntingtina.
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
JP2024503280A (ja) * 2020-12-29 2024-01-25 レボリューション メディシンズ インコーポレイテッド Ｓｏｓ１阻害剤及びその使用
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
JP2025534288A (ja) 2022-09-26 2025-10-15 エッジワイズ セラピューティクス， インコーポレイテッド １，４－ジヒドロキナゾリノン化合物およびその使用
CN116178253A (zh) * 2022-12-26 2023-05-30 重庆医药高等专科学校 一种基于微通道反应器的5,6,7,8-四氢喹啉的合成方法
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2025215450A1 (en) * 2024-04-08 2025-10-16 Sk Biopharmaceuticals Co., Ltd. Thiazole compounds as sodium channel blockers
WO2025252600A1 (en) * 2024-06-04 2025-12-11 Angelini Pharma S.P.A. Activating compounds of potassium channels kv7.2/kv7.3
WO2026006415A1 (en) * 2024-06-27 2026-01-02 Veranova, L.P. Selectively soluble triamide-derived supports for liquid-phase peptide and oligonucleotide synthesis

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3837673B2 (ja) * 1993-12-27 2006-10-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 アントラニル酸誘導体
US5716993A (en) 1993-12-27 1998-02-10 Eisai Co., Ltd. Anthranilic acid derivatives
US5569804A (en) 1993-12-30 1996-10-29 Exxon Chemical Patents Inc (Ecpi) Method to recover cyclic diolefin monomer from its dimer in the production of alkenyl bridged ring compounds
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
NZ523815A (en) * 2000-07-07 2004-07-30 Medicure Int Inc Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
JP2004529943A (ja) 2001-05-15 2004-09-30 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ剤としてのピリジニル縮合二環式アミド
WO2003037274A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
AU2002352878B2 (en) * 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
CA2476936A1 (en) 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
TW200306159A (en) * 2002-03-19 2003-11-16 Du Pont Bicyclic fused pyridinyl amides and advantageous compositions thereof for use as fungicides
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
US7410955B2 (en) 2002-03-25 2008-08-12 Biosynergen, Inc. Therapeutic use of agonist ligands specific to G2A receptor
WO2004007459A2 (en) * 2002-07-12 2004-01-22 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
DE10312073A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen
US8106099B2 (en) 2003-03-18 2012-01-31 Sanofi-Aventis Deutschland Gmbh Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias
US20040192738A1 (en) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
EP1633321A4 (en) 2003-06-18 2006-11-02 Onyx Pharma Inc METHOD FOR CLEANING VIRUS
US20050113576A1 (en) 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
US20050054673A1 (en) * 2003-09-08 2005-03-10 Aventis Pharma Deutschland Gmbh Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
WO2005040100A1 (en) 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
EP1723123A4 (en) * 2004-03-08 2009-12-02 Wyeth Corp ION CHANNEL MODULATORS
WO2005100305A1 (en) * 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
JPWO2005108399A1 (ja) 2004-05-10 2008-03-21 萬有製薬株式会社 イミダゾピリジン化合物
JP2008518968A (ja) * 2004-10-29 2008-06-05 メルク エンド カムパニー インコーポレーテッド アンドロゲン受容体モジュレーターとしてのｎ−（ピリジン−３−イル）−２−フェニルブタンアミド
EA200701745A1 (ru) * 2005-03-17 2008-06-30 Пфайзер, Инк. Циклопропанкарбоксамидные производные
EP2010493B1 (en) 2006-04-12 2016-01-27 Merck Sharp & Dohme Corp. Pyridyl amide t-type calcium channel antagonists
BRPI0710946A2 (pt) * 2006-04-27 2012-03-06 Sanofi-Aventis Deutschland Gmbh inibidores dos canais de Íon task-1 e task-3
EP2038264B1 (en) * 2006-06-29 2016-10-26 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
EP1942104A1 (en) * 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1995241B1 (en) * 2007-03-23 2010-03-17 ICAgen, Inc. Inhibitors of ion channels
AU2008317353B2 (en) 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
JP2011500807A (ja) * 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション ピラジニルアミドｔ型カルシウムチャネルアンタゴニスト
JP2011500808A (ja) * 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
CA2703915C (en) 2007-10-31 2015-02-24 Merck Sharp & Dohme Corp. P2x3 receptor antagonists for treatment of pain
CA2715835C (en) * 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
GB0807772D0 (en) * 2008-04-29 2008-06-04 Lectus Therapeutics Ltd Calcium ion modulators and uses thereof
CN105254557A (zh) * 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物

Also Published As

Publication number Publication date
JP2012528078A (ja) 2012-11-12
RU2011154139A (ru) 2013-07-10
CA2761639A1 (en) 2010-12-02
CN105254557A (zh) 2016-01-20
EP2435407A4 (en) 2013-02-13
JP5685203B2 (ja) 2015-03-18
EP2435407A1 (en) 2012-04-04
CN102448937A (zh) 2012-05-09
MX2011012712A (es) 2012-01-30
HK1217189A1 (zh) 2016-12-30
US20120101105A1 (en) 2012-04-26
US9522140B2 (en) 2016-12-20
CN105130957A (zh) 2015-12-09
US9101616B2 (en) 2015-08-11
HK1217016A1 (zh) 2016-12-16
CA2761639C (en) 2016-06-07
WO2010137351A1 (en) 2010-12-02
US20150322052A1 (en) 2015-11-12
KR20120034658A (ko) 2012-04-12
EP2435407B1 (en) 2019-12-25
KR101605061B1 (ko) 2016-03-21
EP3632899A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
BRPI1015097A2 (pt) uso de um composto, composto, composição farmacêutica, método para tratamento de uma condição ou distúrbio no qual os canais de cálcio do tipo t ou canais de sódio regulados por voltagem estão envolvidos, composto ou um sal farmaceuticamente aceitável do mesmo e uso de um composto ou um sal farmaceuticamente aceitável do mesmo.
BR112012003578A2 (pt) composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal.
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BRPI0819799A2 (pt) Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BRPI0917705A2 (pt) composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BR112015006019A2 (pt) composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção.
BRPI0821274A2 (pt) composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI0822398A2 (pt) Forma sólida, mistura, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou distúrbio e um câncer
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BRPI0815591A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BR112014032510A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto.
BRPI0907977A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BR112012003464A2 (pt) composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.